Compare ADMA Biologics Inc (ADMA) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs British American Tobacco PLC — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while British American Tobacco PLC trades at $61.68 (market cap $132.11B). The key difference: British American Tobacco PLC is far larger — about 62× ADMA Biologics Inc's market cap, and British American Tobacco PLC pays a 5.4% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BTI | |
|---|---|---|
Market Cap | $2.13B | $132.11B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $66.70 |
52-Week Low | $7.60 | $47.93 |
Enterprise Value | $2.20B | $173.34B |
Dividend Yield | — | 5.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
British American Tobacco (BTI) trades at $61.80, up 0.05% on the day, with a bullish technical signal from moving averages and strong support at $61. The company shows robust profitability with a 30.32% net income margin and a 15.74% ROE, though revenue declined to $25.87B in 2024. Recent news highlights a major restructuring with 5,500 job cuts to drive cost savings and growth in non-traditional products like Velo nicotine pouches (Reuters, 2026-06-29).
BTI offers a compelling value with a P/E of 13.34 and a 5%+ dividend yield, supported by 66.7% analyst buy ratings. Key risks include regulatory pressures from the FDA's proposed oversight of foreign tobacco makers (Reuters, 2026-06-26) and volatile earnings, as seen in a 2023 net loss. The stock's outlook is positive for income-focused investors, balancing high margins with transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
